~~<i id='42C1A7C909'><strike id='42C1A7C909'><tt id='42C1A7C909'><pre id='42C1A7C909'></pre></tt></strike></i>~~

Home» leisure time» fashion

fashion

author：fashion 2025-09-29 23:51:11 Page View：39

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Burning questions for the 2024 JPM Healthcare Conference
Next article： Duchenne breakthrough therapy leaves behind pioneering families

explore

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

SANJUAN,PuertoRico--AfederalcontrolboardthatoverseesPuertoRico’sfinancesonFridayapproveda$12.7billio

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Federal weight loss drug coverage is 30 years out of date

ApharmacistholdsaboxofWegovyatapharmacyinProvo,Utah.BloombergphotobyGeorgeFreyFewmedicationshavecapt